INDEX

Note: Page numbers in italics indicate figures; tables are noted with t.

Abbott
   Enlight Biosciences and, 93
   fines levied against, 98
   philanthropy, 105
   R&D budget cuts, 30
Abramson, John, 1, 4, 11, 13, 22
Academic institutions, collaborating with, 91–92
Accountability, 113
ACE inhibitors. See Angiotensin converting enzyme (ACE) inhibitors
Acetaminophen, 2, 7
Acetylsalicylic acid, 7, 8
Actos, 40, 63, 64
AD. See Alzheimer’s disease
Adverse Event Reporting System, 6
Advertising
   direct-to-consumer, 99, 100
   FDA guidelines, 99
   television, 98–100
AIDS, 19, 39, 53, 58, 67
AIM-HIGH trial, 18, 19
Aldose reductase inhibitors, 69
Alimta, 91
Aliskerin, 42, 43, 44
ALK. See Anaplastic lymphoma kinase
Allergic reactions, 41
Alli, 2, 6
Alnylam, R&D budget cuts, 30
Alpha blockers, 42
Alprostadil, 68
ALTITUDE study, 43
Alzheimer’s Association, 57, 58
Alzheimer’s disease, 8, 48, 54, 57–59, 76, 83, 102
cost of care for, 57–58
rising incidence of, 57
American Cancer Society, 54
American College of Obstetricians & Gynecologists, 107
American Heart Association, 15, 18, 21, 62
“America’s Innovative Agency: The FDA” (Hamburg), 34
“America’s Most Generous Companies” (Smith), 105
Anacetrapib, 62
Anaplastic lymphoma kinase, 52
Anemia, Recormin for, 79
Angell, Marcia, 12, 13, 49, 56, 57
Angiotensin 2, 43
Angiotensin converting enzyme (ACE) inhibitors, 42
Anglo-Scandinavian Cardiac Outcomes Trial, 74
Anti-BAFF antibody, 111t
Antibacterial R&D, less investing in, 66
Antibiotics, 19
   bacterial resistance and, 66–67
   novel, GAIN Act and, 67
Antidepressants, 11, 12, 54, 55
Antihistamines, 41–42
Antipsychotics, 54
Apixaban, 91
Arrowsmith, John, 47
Arthritis, 78
ASCOT. See Anglo-Scandinavian Cardiac Outcomes Trial
Aspirin, 7, 8
AstraZeneca, 33, 44, 46, 55, 64, 71, 77
Enlight Biosciences and, 93
R&D budget cuts, 30
tuberculosis campaign, 105
Atherosclerosis, 14, 45, 60
Atorvastatin, 14, 17, 18, 22, 45, 46, 60, 62
Attention deficit disorder medicines, 54
Avanafil, 46
Avandia, 35–36, 40, 63, 64
AVEO Pharmaceuticals, 44
Avorn, Jerome, 98
Azithromycin, 105
Bachmann, Michele, 107
Bacterial infections, 65–69
Bacterial resistance, 65, 66
Bapineuzumab, 59
Bardoxolone, 111t
BBC News, 54
Benadryl, 41
Benign prostatic hyperplasia, saw palmetto and, 8
Benjamin, Regina, 4
Benlysta, 109, 111t
Beta-adrenergic receptor blockers, 82
Beta blockers, 42
Big pharma. See also Drug companies
Big pharma
early research collaborations, 92–93
rare diseases and, 102–104
restoring image of, 96–107
Bill & Melinda Gates Foundation, 104
Bioind, 32
Biomarkers, 93
Biopharmaceutical industry, major impacts on, 26
Biopharmaceutical R&D
cancer treatments and cutbacks in, 53–54
productivity of, 68
Biotech companies, R&D budget cuts, 30
BioWorld, 56
Bisphosphonates, risk-benefit profile of, 21
“Bitter Pill for Big Pharma, A” (Petersen), 73
Blockbusters
changing mentality around, 72–76
defined, 72–73
niche, 74–75
predicting, difficulty in, 73
Blood-pressuring drugs, 42–43
BMI. See Body mass index
BMJ. See British Medical Journal
BMS, 30, 53, 58, 59
Body mass index, 16
Boger, Joshua, 79, 88
Boldrin, Michele, 38
Bone loss, 20–21
BPH. See Benign prostatic hyperplasia
Brain diseases, 54–59
Bristol Myers, merger with Squibb, 28–29, 32
Bristol-Myers Squibb, 64, 105
British Medical Journal, 13, 14, 20
Brody, Howard, 98
Brody, Jane, 20, 21
Budget sparing, outsourcing and, 89–90
Bulpia, Richard, 18
Bupropion, 9, 10, 37
Butte, Atul, 82
C-reactive protein, lowering, Crestor and, 45
Cafepharma, 32
Cancer, 51–54, 83, 102
bundling medications for, 53
as chronic vs. fatal disease, 53, 54
FDA and new drugs for, 36
mortality rates for, 54
targeted therapies for, 52–53
Cancer medications, cost of, 53
Cancer research
“golden era” of, 52
during 1990s, 58
Cancer Research UK, 52
Cannon, Christopher, 60
Capacity generating, outsourcing and, 89, 90
Cardiovascular disease, 60–63
niacin therapy and, 18–19
risk factors for, 21
in United States, 15, 15
CARDS study, 74
Cardura, 87
Carpenter, Daniel, 34
CDC. See Center for Disease Control
CDP. See Coronary Drug Project
Center for Disease Control, 63, 101
Centers for Therapeutic Innovation, at Pfizer, 92
Central nervous system (CNS) research, averting “dead space” in, 56, 57
Cerezyme, 102–103
Cervical cancer, human papilloma virus and, 107
Cetirizine, 41
CETP. See Cholesteryl-ester transfer protein
Chantix, 9, 10, 83, 84
Chemical entities, new, launched in U.S., 1945–2004, 26
Chemotherapy, new agents, 51
Chinese herbal medicines, 8
Chlamydia trachomatis, 105
Cholesterol levels, 21
Cholesteryl-ester transfer protein, finding inhibitors of, 61, 62, 63
Chronic diseases, FDA approved drugs and, 40
Chronicle of Philanthropy, The, 105
Cialis, 46
Claritin, 41
Clinical development programs, studies and costs tied to, 110–111
Clinical outcomes, predicting, difficulty in, 78
Clinical trials
data in public registries, 102
drug company funding for, 11
high placebo efficacy rates in, for psychiatric disorders, 13
transparency and, 100
ClinicalTrials.gov, 11, 13, 14
Clostridium difficile, 67
Collaboration
academic institutions and, 91–92
precompetitive, 93
Collins, Francis, 50
“Comparative Effectiveness of Weight-Loss Interventions in Clinical Practice,” 16
Consultants, 82–84
Contrave, 37
Coronary Drug Project, 18
Corporate reputation, drug pricing, profitability and, 97
Cost-cutting culture, R&D and, 94–95
Coukell, Allan J., 102
Credibility, 14
Crestor, 18, 44, 45, 46
Crizotinib, 52, 74, 75, 83, 111t
Crum, Alia, 13
CVD. See Cardiovascular disease
Cynicism, 98, 105
Cystic fibrosis, 50, 102
“Cytisine for Smoking Cessation” (Etter), 10
Cytisine preparation, smoking cessation and, 9, 10
Cytisus laborinum L, poisoning incidents and, 9–10
Cytosine, 83, 84
DALYs. See Disability adjusted life years
Dana Farber Cancer Institute, 54
Dapagliflloxin, 64
Darapladib, 111t
Data Safety Monitoring Board, 43, 62
Davis, Pamela, 50
“Debate Re-ignites Contribution of Public Research to Drug Development,” 49
“Decade of the Brain,” 54
Deen, Paula, 98
Dementia, Ginkgo biloba trial and, 8
Department of Health and Human Services, 49
Depression, 54, 55, 56, 69
healthy diet, active lifestyle and, 15 major, 11
Diabetes, 63–65, 82, 102
FDA and new drugs for, 35, 36
healthy diet, active lifestyle and, 15
Diet, 15
cardiovascular disease and, 21
obese population and, 16, 17
Diet drugs, FDA and stance on, 36–37
Dietary supplements, U.S. sales of, 8
Diflicid, 67
Diflucan, 87
Diphenhydramine, 41
Direct-to-consumer advertising, 99, 100
Disability adjusted life years, mental illness and, 55, 55
Discovery, productivity and, 85–87
Discovery industrialization, success of, 84
Disease, worldwide burden of, disability adjusted life years, 55
“Disease creep,” 21
“Disease Creep: How We’re Fooled into Using More Medicine Than We Need” (Lenzer), 21
“Disease mongering,” 19, 20
Diuretics, 42
Doctors, as gatekeepers for patients’ medications, 22
Doshi, Peter, 101
Downsizing, 29
Doxepin, 41
DPP-IV inhibitors, 100
Dr. Oz Show, The, 1, 22, 106, 113
“Dr. Oz’s Four Secrets,” 3
Drug approvals, from companies that no longer exist, 27, 27. See also Food and Drug Administration
Drug “cocktails,” for cancer, 53
Drug companies
controlling information your doctor gets, 5, 10–14
prescribing drugs you don’t need, 5, 14–19
targeting symptoms, not causes, 5, 19–22
underestimating dangerous side effects and, 5–10
Drug delivery technology, 93
Drug lags, 26
Drug repositioning, filling R&D pipeline and, 80–82
Drug repurposing, 80
Drug-resistant pathogens, 65
Drug Truths—Dispelling the Myths About Pharma R&D (LaMattina), 1
Drugs
discovery of
perspective on, 68–69
“shots on goal” philosophy in, 86
illegal detailing of, 97–98
price regulation for, 39
risk–benefit profiles of, 6
DSMB. See Data Safety Monitoring Board
Dyslipidemia, 18
ED. See Erectile dysfunction
Effectiveness of drugs, transparency and, 101
Eisai, malaria campaign, 105
Ekblom, Anders, 77
Eli Lilly, 33, 58, 59, 63, 77, 91
Enlight Biosciences and, 93
fines levied against, 98
philanthropy, 105
strong R&D investments at, 112
tuberculosis campaign, 105
Employees, mergers and social consequences on, 31–33
Enlight Biosciences, partners invested in, 93
Entrega, 93
“Epidemic of Mental Illness–Why?, The,” (Angell), 12
Erectile dysfunction, 80
drugs for, 46, 79
TV ads for, 99
Etter, J. F., 9
European College of Neuropsychopharmacology, 56
Exercise, 15
cardiovascular disease and, 21
obese population and, 16, 17
Famotidine, 90
FDA. See Food and Drug Administration
Federal deficit, NIH budget cuts and, 53–54
Federal Trade Commission, 30
Fen-phen, 36
Fertility rates, placebos and, 13
Fidaxomicin, 67
Financial toxicity, 53
Fines, for illegal marketing practices, 98
Firestone, Raymond, 32
Fisons, 29
5-lipoxygenase inhibitors, 69
Food and Drug Administration, 2, 46
advertising guidelines, 99
declining number of approvals by, 109
diabetes drugs and, 64–65
drug approval system of, 6, 7
drug sponsors and, 100
heightened requirements for NDAs by, 34–41
new antibiotics and, 67
new drug approvals by, 25, 97
new medical entities approved by, 26–27
rolling 10-year drug approvals, 2010–2019, 110
safety data requirements by, 110–111
unfair criticisms of, 39–40
Vertex approved by, 50
INDEX 119

Fortune magazine, 7, 96
“Four Secrets That Drug Companies Don’t Want You to Know” (Oz), 5–22, 23
Framingham Heart Study, 60
Frazier, Kenneth, 33, 112
Freund, John, 34, 35, 36
FTC. See Federal Trade Commission
Funtleyder, Les, 112
Fusion mergers, 31
GAIN Act, 67
Gamma secretase inhibitors, 58, 59
Garber, Judy, 54
Gardasil, 107
Gauger disease, 102
Gender, cancer mortality rates and, 54
Generic drugs
cost of, 45
safety issues and, 6–7
Genetically targeted drugs, 75–76
Genzyme, 102, 103
Gingko Evaluation of Memory (GEM) trial, 8
Ginkgo biloba, 8, 10
GlaxoSmithKline, 33, 55, 109
Avandia sales and, 35, 36
fines levied against, 98
malaria campaign, 105
rare diseases and, 103
tuberculosis campaign, 105
Globalization, 88
Goddard, Colin, 88
Goodwin, Guy, 56, 57
Gottlieb, Scott, 82, 83
“Grasping for Any Way to Prevent Alzheimer’s,” 59
Grassley, Chuck, 36, 39
Growth, 88
Gutierrez-Ramos, Jose Carlos, 92
Ha-Ngoc, Tuan, 44
Hajek, Peter, 10
Hamburg, Margaret, 34
Hamilton Rating Scale for Depression, 12
Haussen, Harald zur, 107
HDL cholesterol, 18, 36, 45, 60–61
Health-care system, War on Cancer and, 53
Heart attacks, 14, 17, 21, 22
Heart disease
deaths attributable to, in U.S. 1900–2008, 15
FDA and new drugs for, 36
Heart Protection Study (HPS) Collaborative Group, 17, 18
Herbal medicines, 8, 10
Herper, Matthew, 43, 107
HGS. See Human Genome Sciences
High-throughput screening, 84, 92
Hiring freezes, 31
Hirth, Peter, 78, 79
HIV drugs, FDA approval of, 39
Hoechst, 29
Hogan, Melissa, 103, 104
HPV. See Human papilloma virus
HRSD. See Hamilton Rating Scale for Depression
HTS. See High-throughput screening
Human Genome Project, 3, 25, 84
Human Genome Sciences, 109
Human papilloma virus, cervical cancer and, 107
Hypertension drugs, 42–43
Ibuprofen, 111
IDSA. See Infectious Diseases Society of America
Iduronate sulfatase, 103
IFPMA. See International Federation of Pharmaceutical Manufacturers & Associations
Illegal detailing, of drugs, 97–98
Imaging techniques, 93
IMT. See Inflammatory myofibroblastic tumor
“In Defense of Antidepressants” (Kramer), 57
In-licensing, 90–91
“In the Pipeline” blog (Lowe), 33
Industry-physician relationship, transparency and, 101–102
Industry productivity, royalties and, 78–80
Infectious diseases, 65
global deaths from, leading causes of, 66, 66
Infectious Diseases Society of America, 66
Inflammatory myofibroblastic tumor, ALK oncogene and, 52
Influenza, 101
Inlyta, 86
Innovation, 88–89, 109
Intellectual property, 30
International Federation of Pharmaceutical Manufacturers & Associations, 105
International Trachoma Initiative, 105
Iressa, 84
“Isl Declining Innovation in the Pharmaceutical Industry a Myth?”
(Schmid and Smith), 25
ITI. See International Trachoma Initiative
Ivacaftor, 74
Ivermectin, 104
JAK-3, 81
JAMA. See Journal of the American Medical Association
Janumet, 100
Januvia, 84, 100
Jarvik, Robert, 99
Jefferson, Tom, 101
Johnson & Johnson, 58, 59
Enlight Biosciences and, 93
philanthropy, 105
in top 10 of Fortune’s list, 96
Journal of the American Medical Association, 8, 9, 60
Kefauver-Harris Drug Act, 25
Kessler, David, 73, 107
Kidney cancer, drugs for, 44, 79
Kramer, Peter, 57
Kumar, Harpal, 52
Lactose intolerance, 6
Lancet, The, 17, 63
Langer, Ellen, 13
Latanoprost, 68
Lawsuits, 105
Layoffs, mergers and, 32, 33
LDL cholesterol, 18, 45
Lipitor and, 73–74
lowering, 60, 77
statins and, 17, 43–44
Leads, 84
Lechleiter, John, 33, 98, 112, 113
Lehman, Richard, 14
Lenze, Jeane, 21, 22
Leprosy, thalidomide and, 81–82
Levitra, 46
Linezolid, 67
Lipid metabolism, PCSK9 and, 60
Lipitor, 14, 17, 19, 29, 44, 62, 73, 74, 91
biochemical profile of Crestor vs., 46
sales of, at its peak, 87
success of, factors related to, 45
TV ads for, 99
Liver failure, acetaminophen and, 7
Loder, Elizabeth, 14
Loratidine, 41
Lowe, Derek, 33
Lung cancer
ALK gene and, 52
crizotinib and, 74–75
Mackay, Martin, 71
Major depression, 11, 55
Malaria, combating, 105
Mandel, Michael, 88
Mann, John, 11, 55
Marion Merril Dow, 29
McKinnell, Hank, 73
Mectizan, 104, 105
“Medical Management of Depression, The”
(Mann), 11, 55
Medicare, 9, 45
Medimmune, Astra Zeneca acquisition of, 30
Melanoma
new therapies for, 53
vemurafenib for, 75
Zelboraf for, 79
Men, cancer mortality rates for, 54
Menon, Rosalyn, 1
Menotabine, 111t
Mental illness, 55
Methicillin-resistant Staphylococcus aureus, 67
Miller Taback Health Care Transformation Fund, 112
Misoprostil, 68
Moynihan, Ray, 20, 21
MPS. See Mucopolysaccharidosis
MRSA. See Methicillin-resistant Staphylococcus aureus
Mucopolysaccharidosis, 103
Multiple sclerosis, 102
Muscular dystrophy, 102
Naltrexone, 37
Nanotechnology, 93
Naproxen, 110
National Alzheimer’s Project Act, 23
National Cancer Act, 51
National Cancer Institute, 51, 107
National Health Service, Britain, 9
National Institutes of Health, 23, 49, 58
antibacterial R&D and, 67
biomedical research funding and, 50
budget cuts at, 53–54
diabetes drug development and, 64
rare diseases defined by, 102
Native American healers, 8
Nature, 41
Nature Biotechnology, 49
NaV1.7, 77, 78
NDAs. See New Drug Applications
Negative data, credibility of pharmaceutical industry and, 14
Nerve growth factor, 78
Neuroscience research, scaling back on, reasons for, 55–56
“New Bargain for Drug Approvals, A” (Boldrin and Swamidass), 38
New development project success rates, 47
New Drug Applications, 40, 47, 111, 112
filing, 6
heightened FDA requirements for, 25, 34–41
New England Journal of Medicine, The, 9, 11, 12, 16, 17, 18, 49, 50, 55, 61
New medical entities, FDA approval of, 26–27
New York Review of Books, The, 12
New York Times, 8, 21
Nexavar, 44
NGF. See Nerve growth factor
Niacin
heart disease and debate over, 18–19
side effects with, 18
“Niacin at 56 Years of Age—Time for an Early Retirement?” 19
Niblack, John, 85
Niche blockbusters, 74–75
Nicotine, 10
Nicotine partial agonists, 83
NIH. See National Institutes of Health
Nissen, Steven, 62
Nitrous oxide, 80
Nixon, Richard, 51, 54
NMEs. See New medical entities
NO. See Nitrous oxide
Non-Hodgkin’s lymphoma, ALK-positive, 52
Nonsteroidal anti-inflammatory drugs, 82, 110–111
Norvasc, 29, 87
Novartis, 42, 43, 44, 55
malaria campaign, 105
tuberculosis campaign, 105
Novel drugs, recently approved and in pipeline, 111r
Novo Nordisk, Enlight Biosciences and, 93
NSAIDs. See Nonsteroidal anti-inflammatory drugs
Nutt, David, 56, 57
Obama, Barack, 23
Obama administration, Alzheimer’s disease research and, 58
Obesity, 82
FDA and new drugs for, 35, 36, 37
type 2 diabetes and, 15, 16, 63
“Off the Mark” (Parisi), 4
Omeprazole, 90
Oncogene Sciences Institute, 88
Oncogenes, 51
Orilstat, 2
Orphan diseases, 69, 76
Osborne, John, 43
Osteoarthritis, healthy diet, active lifestyle and, 15
Osteopenia, 20–21
Osteoporosis, 20
FDA and new drugs for, 36
healthy diet, active lifestyle and, 15
Outcome studies, 37
Outsourcing
  pharma R&D and, 89–92
  purposes of, 89
Overdosed America (Abramson), 1, 4, 11
Oz, Dr., 2, 4, 5, 8, 14
PAF. See Platelet activating factor
Pain, 69
Pain sensitivity, treating, 77–78
Parisi, Mark, 4
Pathogens, drug-resistant, 65
Payers, higher hurdles set by, 41–46
PCSK-9 inhibitors, 46, 80, 81, 83–84
PDUFA. See Prescription Drug User Fee Act
Peanut allergies, 6
Pepcid, 90
Pereira, Dennis, 84
Permutter, Roger, 60
Perry, Rick, 107
Petersen, Melody, 73
Pfizer, 9, 34, 46, 52, 55, 58, 59, 61, 62, 73, 80, 81, 83, 84, 85
  CARDS study, 74
  Centers for Therapeutic Innovation, 92
  Enlight Biosciences and, 93
  fines levied against, 98
  Lipitor’s success and, 44, 45
  malaria campaign, 105
  new, 29, 29
  oncology pipelines at, 86
  philanthropy, 105
  pipeline updates, 30
  rare diseases and, 103
  R&D budget cuts, 29
  “Science Ambassadors” program at, 106
  “shots on goal” philosophy at, 86–87
  size and productivity at, 87–89
  substance P antagonists and, 69
  in top 10 of Fortune’s list, 96
Pharmaceutical companies, TV ads and, 98–100
Pharmaceutical industry
  consolidation of, 26–34, 28
  R&D cuts and, 112–113
Pharmaceutical Research and Manufacturers Association, 27, 28, 35, 51–52, 106
Pharmacia, 34
Pharmacoeconomics groups, 42
Pharmacovigilance programs, 6
Phase 4 studies, 110
Phenothiazines, 82
Phenotypic screening, 83
Philanthropy, pharmaceutical companies and, 104–105
PhRMA. See Pharmaceutical Research and Manufacturers Association
PHT. See Pulmonary hypertension
Pipelines
  “industrialized” methodology and, 84
  mergers, reorganizations and, 30
  outsourcing and, 89, 90, 91
  “Placebo-Controlled Trial of Cytoisine for Smoking Cessation,” 9
Placebo efficacy rates, high, in clinical trials for psychiatric disorders, 13
  “Placebo Response in Studies of Major Depression,” 12
Platelet activating factor, 68
Plavix, 73
Plexxikon, 78
Poison Control Center, 7
Polysaccharides, incomplete breakdown of, 103
Precompetitive collaborations, 93
Predictive innovation, success rates and, 76–78
Prescription Drug User Fee Act, 26, 40, 111–112
Prices of drugs, regulation of, 39
Prilosec, 90
Productivity
  discovery and focus on, 85–87
  mergers and impact on, 32–34
  surge in, 109, 110, 113
Progressive Policy Institute, 88
Promoting drugs, for labeled indications, 97–98
Prostaglandins, 68
Psoriasis, tofacitinib and, 81
Psychiatric disorders, high placebo efficacy rates in clinical trials for, 13
Psychiatric medications, controversy over, 54, 57
Public confidence, restoring, 113
Public registries, clinical trial data entered into, 102
Public sector research, number of drug approvals rooted in, 49–50
Pulmonary hypertension, primary, 80–81
PureTech Ventures, 93

Queen Mary University Hospital, London, Tobacco Dependence Unit, 10

Rare diseases, big pharma and, 102–104
Rasilez, 42

R&D budget cuts in, 29–30
consolidations and turmoil in, 112
cost-cutting culture and, 94–95
evolutionary thinking in, 94
identifying fatal flaws in compounds, 94
need for substantial investment in, 112–113
outsourcing and, 89–92
productivity, 25–48
current critics of, 25
heightened FDA requirements for NDAs and, 34–41
higher hurdles set by payers and, 41–46
mergers and impact on, 26–34
size and, 87–89
science ambassadors and, 105–106
R&D pipeline, drug repositioning and, 80–82
Read, Ian, 85
Recormin, for anemia, 79
Redfern, David, 33

“Reminder on Maintaining Bone Health, A” (Brody), 20–21
Renin-angiotensin (RAS) cascade, 42–43
Renin inhibition, 42
Reorganizations, R&D divisions and, 30–31

Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA (Carpenter), 34
Resource pooling, 92
Return on investment, 42
Reusable drugs, 80
Revatio, 81
Rezulin, 40
Rheumatoid arthritis, tofacitinib for, 81, 84, 110, 111
Rhone-Poulenc, 29

Rinat, 78
Risk-benefit profiles, 6, 21
River blindness, 104–105
Roche, 53, 75, 79, 101
Rockoff, Jonathan, 74, 75
ROI. See Return on investment
“Role of Public-Sector Research in the Discovery of Drugs and Vaccines, The,” 49–50
Rorer, 29
Rosenthal, Elisabeth, 99
Rosuvastatin, 45
Roussel-Uclaf, 29
Royalties, scientific productivity and, 78–80
Rumors, 32
Russell, Angus, 42

Safety data, FDE requirements for, 110–111
Sage Therapeutics, 57
Salicylic acid, 8
Sanofi-Aventis, 29, 35, 55, 92
Genzyme acquired by, 103
malaria and tuberculosis campaigns, 105
SATURN trial, 45
Saw palmetto, 8–9, 10
Saw Palmetto Treatment for Enlarged Prostates (STEP) trial, 8–9
Scannell, Jack, 83, 84
Schering-Plough, 29, 33, 112
Schizophrenia, 54, 56
Science ambassadors, 105–106
Scripps Research Institute, Pfizer collaboration with, 92
Searle, 29, 29, 68
Semagacestat, 59
Serenoa repens, 8
SGLT2, 64
Sheskin, Jacob, 81
“Shots on goal” philosophy, at Pfizer, 86–87
“Should Patents on Pharmaceuticals Be Extended to Encourage Innovation?” 96
Side effects, 5–10, 97
Sildenafil, 80, 84
Silverman, Ed, 100
Simpson, Stephen D., 71, 72
Simvastatin, 14, 17, 22
Singulair, 29
Sitagliptin, 100
Site closures, 94
Size
  benefits of, 88
  negative aspects of, 88
  R&D productivity and, 87–89
Skyline Ventures, 34
Smith, Jacquelyn, 105
Smoking addiction, treating, 83
Smoking cessation, cytisine preparation and, 9, 10
Southworth, Paul, 55
Squibb, Bristol Myers merger with, 28–29, 32
St. John’s wort, 10
Statins, 4, 5, 14, 15, 17, 18, 19, 21, 44, 60
Stipp, David, 7
Stroke, 14, 17, 21, 22
Substance P antagonists, 68–69
Super Bowl commercials, 98
Sutent, for kidney cancer, 79
Swamidass, S. Joshua, 38
Synergy (downsizing), 29, 31
Synthelabo, 29

T/A, study results for, 61–62. See also
  Atorvastatin; Torcetrapib
Tabex, 9, 10
“Take Two Possibly Lethal Pills and Call Me in the Morning” (Stipp), 7
Tamiflu, 101
Tanezumab, 78
Tarceva, 84, 86
Targeted drugs, 75–76
Taylor, Edward C., 91
Tedizolid, 67
Tekturna, 42
Television advertising, 98–100
Thalidomide, repositioning of, 81–82
“Therapy for Cystic Fibroses—The End of the Beginning,” 50
Thomson Reuters, 47
Time magazine, 35
Tivozanib, 44
Tofacitinib, 81, 84, 110, 111t
Torcetrapib, 61, 62, 77
Torreele, Els, 96
Trachoma, 105
Traditional medicines, modern drug industry and, 8
Transparency, need for, 100–102

“Treating to New Targets” study, 73
Triglycerides, 18
Trius Therapeutics, 67
Tropical diseases, 104
Tuberculosis, combating, 105
“Two-Year Randomized Trial of Obesity Treatment in Primary Care Practice, A,” 16
Tylenol, 2, 7
Type 2 diabetes
  increase in, globally, 63
  obesity and, 15, 16

UNICEF, 104
United States deaths attributable to heart disease in, 1900–2008, 15
  increase in obesity and Type 2 diabetes in, 16
  new chemical entities launched in, 1945–2004, 26
Upjohn, 29, 29, 68

Varenicline, 9, 83
Vasodilation, sildenafil and, 80
Vemurafenib, for melanoma, 75, 111t
Vertex, 50, 79, 88
Viagra, 19, 29, 46, 79, 80, 87
Victoza, 98
Victrelis, 111t
Viehbacher, Chris, 35
Vioxx, 47, 107
Vitamin B3, 18
Vivus, 46

Wall Street Journal, 13, 34, 38, 96, 109, 110
Wang, Shirley, 13
War on Cancer
  new business models and, 53
  research funded by, 51
Warner-Lambert Parke-Davis, 29, 29, 34, 73, 91
Weight loss
  FDA and new drugs for, 35, 36, 37, 38
  obese population and, 17
  placebos and, 13
West, Robert, 9
Weyland, Simone, 41
“Why Placebos Work Wonders” (Wang), 13
Williams, John, 84
Williams, Mike, 56
Winfrey, Oprah, 4
Women, cancer mortality rates for, 54
Woodcock, Janet, 109, 111, 113
World Bank, 104
World Health Organization, 55, 104, 105
Wyeth, R&D budget cuts, 29, 30
Xalkori, 52, 74, 83, 86
Xanax, 29
Xarelto, 111
Xenical, 2
Yervoy, 111
Zantac, 90
Zelboraf, for melanoma, 79
Zithromax, 87, 105
Zocor, 14
Zoloft, 87
Zyprexa, 73
Zyrtec, 41
Zyvox, 67